PACAP Related Peptide (1-29) vs VIP

How they're alike

VIP and PACAP-family peptides belong to the same superfamily of class B G protein-coupled receptor ligands — the VIP/secretin/glucagon family — and share overlapping receptor pharmacology (Liao 2019). Both engage receptors that couple to Gαs, raising intracellular cAMP and activating downstream cascades including adenylyl cyclase, phospholipase C, MEK/ERK, and Akt (Liao 2019). The functional overlap is real at the receptor level: the VPAC1 and VPAC2 receptors respond to both PACAP and vasoactive intestinal polypeptide, while PAC1R responds preferentially to PACAP-family ligands (Sundrum 2018). The cryo-EM structure of the activated human VIP1 receptor was solved in complex with PACAP27 rather than VIP itself, illustrating how PACAP peptides can engage VPAC-family receptors in addition to PAC1R (Duan 2020). Both ligand families also map onto a 23-amino-acid stretch where a local BLOSUM62 alignment of the two card sequences shows 26.1% identity, consistent with descent from a common ancestral peptide hormone scaffold.

How they differ

The most consequential difference is receptor selectivity and downstream tissue distribution. VIP signals primarily through VPAC1 and VPAC2 — class B GPCRs widely expressed in immune cells, gut, lung, and brain — and the VPAC axis is the entry point for its immunomodulatory, vasodilatory, and bronchodilatory effects (Couvineau 2012; Martínez 2019). PACAP Related Peptide (1-29) by contrast is described as a PAC1R-selective endogenous fragment expressed in the paraventricular nucleus (PVN) and is used as a probe for PAC1R-mediated stress-circuit signaling implicated in PTSD-like fear sensitization and migraine (Hammack 2015; Sundrum 2018). The two receptor branches map onto distinct dominant biologies: VPAC-driven signaling is most prominent in peripheral immune and epithelial regulation (Smalley 2009; Iwasaki 2019), while PAC1R-driven signaling is most prominent in central stress circuits and trigeminovascular pain (Hammack 2015; Sundrum 2018).

The two peptides also differ sharply in their human-evidence profile. VIP has been studied extensively in patients — including controlled trials of inhaled aviptadil in pulmonary hypertension, intravenous aviptadil in COVID-19 ARDS (including TESICO), and intranasal VIP in Graves' disease and rheumatoid arthritis (Iwasaki 2019; Martínez 2019). PACAP Related Peptide (1-29), as a rat-derived endogenous fragment, has not entered human therapeutics; its literature is preclinical and centred on PAC1R receptor pharmacology and stress/migraine circuits (Hammack 2015; Liao 2019; Sundrum 2018). Mechanistically, VIP also engages broader immunological pathways — induction of regulatory T cells, suppression of TNF-α/IL-6/IL-12, NF-κB inhibition — that are documented across cell and animal studies (Smalley 2009; Martínez 2019; Tan 2015), whereas PACAP-family work emphasises adenylyl cyclase, phospholipase C, MEK/ERK and Akt signaling pathways converging on PAC1R (Liao 2019). Finally, the underlying sequences are only weakly conserved at the residue level (26.1% identity over a 23-aa stretch), indicating that any therapeutic agent designed against one receptor branch should not be assumed to cross-react meaningfully with the other without empirical confirmation.

Head-to-head clinical evidence

There are no head-to-head clinical trials comparing VIP and PACAP Related Peptide (1-29). The PubMed head-to-head candidate set for this pair is empty, and the two cards share no refs in common. The closest direct comparisons in the available literature are mechanistic and structural rather than clinical: the Duan 2020 cryo-EM study of the VIP1 receptor was solved with PACAP27 rather than VIP, providing structural evidence that PACAP-family ligands productively engage VIP receptors (Duan 2020). The Sundrum 2018 review of the trigeminovascular system explicitly contrasts the three receptors of this family — PAC1R, which responds preferentially to PACAP, and VPAC1 and VPAC2, which respond to both PACAP and VIP — and is the most relevant cross-comparison paper in the dossier (Sundrum 2018). The Liao 2019 PAC1R review situates PAC1R within the VIP/secretin/glucagon family of GPCRs and surveys the disease areas where PAC1R targeting has been pursued (Liao 2019). No comparative efficacy data, no clinical endpoint comparisons, and no indirect meta-analyses bridging the two peptides are present in the dossier.

Safety profile comparison

The two peptides occupy very different safety-data regimes. VIP has documented clinical safety signals from human exposure: nasal congestion with intranasal formulations, mild diarrhea, flushing consistent with vasodilatory pharmacology, and clinically meaningful hypotension at pharmacologic doses (Iwasaki 2019; Martínez 2019). VIP's potent vasodilator activity makes hemodynamic instability — and additive hypotension with other vasodilators — the dominant safety concern. PACAP Related Peptide (1-29), in contrast, is a research peptide without a human safety dataset in the dossier; its safety profile is undefined for human exposure, and inferences from PACAP-family pharmacology (such as PACAP's known role in migraine attack provocation in susceptible individuals) cannot be transferred directly to this specific 29-residue fragment without dedicated study (Sundrum 2018). Neither peptide has a boxed warning or other regulatory safety designation, because neither has received regulatory approval for any indication.

Indication overview

Neither peptide is approved by the FDA, EMA, or any other major regulatory authority for any indication. VIP (as the synthetic form aviptadil) has been investigated in human clinical trials across pulmonary hypertension, COVID-19 ARDS (including the TESICO RCT), rheumatoid arthritis, and Graves' disease, but none of these programmes has yielded an approved indication; the FDA declined an Emergency Use Authorization for IV aviptadil in COVID-19 ARDS in 2021 (Iwasaki 2019; Martínez 2019). The PACAP/VIP receptor family is an active drug-discovery target — PAC1R has been pursued for neurological and metabolic disorders (Liao 2019), and VPAC1/VPAC2 are being explored for inflammatory and autoimmune diseases (Martínez 2019; Gomariz 2019) — but the PACAP Related Peptide (1-29) itself is described in the dossier as an endogenous fragment used to probe PAC1R signaling rather than as a therapeutic candidate.